Monrovia, Liberia – The Liberia Medicines & Health Products Regulatory Authority (LMHRA) and stakeholders from around Africa are in Liberia for a conference on Pharmacovigilance and Clinical Trials. The two-day pharmacovigilance and clinical trials conference provides a forum for partners and health officials to debate on medicinal product regulations in Liberia, with an emphasis on public health and safety.
Under the topic “Medicine Safety Monitoring and Clinical Trial Oversight in Emerging Regulatory System,” the conference, which began on Monday, September 1, 2025, will conclude today, Tuesday, September 2, 2025, at the EJS Ministerial Complex in Congo Town.
The conference’s goals are to promote innovation, teamwork, and a common dedication to enhancing patient safety and furthering clinical research, according to LMHRA Managing Director Luke L. Bawo. It also hopes to stimulate fresh concepts and partnerships through thought-provoking talks and active participation from attendees.
“The event is important because it brings together professionals from a variety of fields, including clinical research, healthcare providers, regulatory bodies, lawmakers, and industry leaders,” he said.
In his overview of the conference, Dr. Juwe D. Kercula, Manager CT/PV and Chairman of the Conference Organizing Committee, said, drugs and other products made for use in agriculture, medicine, health, and science must be closely watched because they have an impact on public health. According to Dr. Kercula, the conference will cover topics such as the utilization of medical items in Liberia, their monitoring, and the clinical studies they undergo.
Dr. Malayah Tamba Chieyo, Deputy Minister for Technical Services, Ministry of Health, spoke on behalf of Liberia’s Health Minister and explained that the meeting of industry stakeholders, researchers, thought leaders, and regulatory experts offers a rare chance to discuss all clinical advancements, innovations, and difficulties in the field.
He went on to say that pharmacovigilance is a cornerstone of the collective dedication to patient safety, clinical research integrity, and medical practice, rather than just a legal necessity. According to him, vigilance is the science and practice of detecting, assessing, understanding and preventing others effects on or other drug related problem.
Jenny Marekera, of Zimbabwe’s Medicines Control Authority, also conveyed gratitude for the invitation to the stakeholders’ conference on clinical trials and pharmacovigilance, emphasizing the significance of guaranteeing high-quality, safe, and effective medical products.
Speaking, Dr. Hasifa Tapi, President of the West African Postgraduate College of Pharmacists, emphasized the college’s dedication to patient safety, medication safety, and ongoing training while praising the conference for promoting education and professional development.
Both speakers underscored the significance of the gathering and the contributions of various stakeholders.
In his Goodwill message, Robert Rutaisi, Rwanda FDA Managing Director addressed the conference on medicine safety monitoring and clinical trial oversight in emerging regulatory systems, emphasizing the importance of shared experiences and partnerships among regulators, researchers, and scientists.
He highlighted Rwanda’s commitment to advancing pharmacovigilance and clinical trials oversight in line with international standards while remaining regionally responsive.
Reported by: Prince Saah
